| VRTX Stock | | | MXN 9,577 310.12 3.35% |
Chairman
Dr. Jeffrey M. Leiden, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Vertex Pharmaceuticals Incorporated. He has held the positions of Chief Executive Officer and President since February 2012 after joining us as CEO Designee in December 2011. He was a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences VC firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden serves as a director of Quest Diagnostics Inc., a medical diagnostics company, and Massachusetts Mutual Life Insurance Company, an insurance company. Dr. Leiden was a director and the nonexecutive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012 since 2020.
| Age | 63 |
| Tenure | 4 years |
| Professional Marks | Ph.D |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Leiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
0.1733 % which means that it generated a profit of $0.1733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.2767 %, meaning that it generated $0.2767 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Vertex Pharmaceuticals has accumulated 893.85
M in total debt with debt to equity ratio
(D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Vertex Pharmaceuticals has a current ratio of 4.52, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vertex Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Vertex Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vertex Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vertex to invest in growth at high rates of return. When we think about Vertex Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company was founded in 1989 and is headquartered in Boston, Massachusetts. VERTEX PHARMACEUTICAL operates under Biotechnology classification in Mexico and is traded on Mexico Stock Exchange. It employs 3400 people. Vertex Pharmaceuticals (VRTX) is traded on Mexican Exchange in Mexico and employs 4,800 people.
Management Performance
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | |
| Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | |
| Michael Parini, Executive Vice President, Chief Legal and Administrative Officer | |
| Alan Garber, Independent Director | |
| Mike Tirozzi, SVP Officer | |
| Damian Esq, Chief VP | |
| Jeffrey MD, Ex Chairman | |
| MD FASN, Pres CEO | |
| Stuart BSc, Ex COO | |
| John Gray, Senior Vice President Genetic Therapies | |
| Margaret McGlynn, Independent Director | |
| Diana McKenzie, Independent Director | |
| Sangeeta Bhatia, Independent Director | |
| Terrence Kearney, Independent Director | |
| Nia Tatsis, Senior Vice President Chief Regulatory Officer | |
| Kristen Ambrose, Tax, Accounting | |
| Paul Silva, Senior Vice President Corporate Controller | |
| David Altshuler, Executive Vice President - Global Research, Chief Scientific Officer | |
| Amit Sachdev, Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO | |
| Charles Wagner, Chief Financial Officer, Executive Vice President | |
| Gerald Bruce, Executive Vice President Commercial Operations | |
| Ourania Tatsis, Ex Officer | |
| Bruce Sachs, Co-Lead Independent Director | |
| Susie Lisa, VP Relations | |
| Lloyd Carney, Independent Director | |
| Yuchun Lee, Independent Director | |
| Stuart Arbuckle, Executive Vice President Chief Commercial Officer | |
| Carmen Bozic, Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer | |
| Jeffrey Leiden, Chairman of the Board, President, Chief Executive Officer | |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Vertex Stock Analysis
When running Vertex Pharmaceuticals' price analysis, check to
measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.